1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Species | Human |
| Cat.No | ABC-TC0886 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
OVSAHO is a permanent human ovarian carcinoma cell line derived from solid tumors of serous papillary adenocarcinoma. It serves as a reliable in vitro source for High-grade serous carcinoma research. OVSAHO cells are versatile, displaying successful transplantation capabilities in nude and immune-competent mice through intraperitoneal, subcutaneous, and orthotopic heterotransplantation. The cell line expresses various cytokeratin polypeptides, including CK 6, 7, 8, 14, 18, 19, and 15 and/or 16. 
Histological examination of OVSAHO tumors reveals sheets or papillary structures comprising atypical cells with oval to spindle shapes.
Why choose OVSAHO from AcceGen?
AcceGen’s OVSAHO cell line stands out as an ideal choice due to its exceptional attributes. With each vial containing more than 1×106 of viable cells, researchers can confidently proceed with their experiments knowing they have ample material to work with. Rigorous testing confirms human origin and absence of interspecies contamination and infectious diseases. Additionally, STR analysis verifies the unique identity of the cell line, ensuring reliable research outcomes.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The OVSAHO cell line holds significant applications in ovarian cancer research. As one of the frequently employed tumor models, it plays a crucial role in pre-screening experimental anticancer agents in vitro. Researchers can rely on OVSAHO to explore specific histologic subtypes and the response to various agents. Additionally, OVSAHO’s utility extends to xenograft models, where its implantation in experimental platforms aids in preclinical drug development, contributing to the advancement of ovarian cancer treatment strategies.
